Dyadic International Inc. (NASDAQ:DYAI) Sees Significant Growth in Short Interest

Posted by Geri Gentry on Jun 11th, 2026

Dyadic International Inc. (NASDAQ:DYAI – Get Free Report) saw a significant increase in short interest in the month of May. As of May 29th, there was short interest totaling 622,465 shares, an increase of 754.7% from the May 14th total of 72,829 shares. Approximately 2.2% of the company’s stock are short sold. Based on an average daily trading volume, of 1,064,040 shares, the days-to-cover ratio is presently 0.6 days.

Institutional Investors Weigh In On Dyadic International

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC lifted its position in Dyadic International by 13.7% during the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after acquiring an additional 36,266 shares during the last quarter. Marathon Capital Management lifted its position in Dyadic International by 142.9% during the fourth quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 50,000 shares during the last quarter. Apis Capital Advisors LLC purchased a new stake in Dyadic International during the third quarter valued at approximately $1,817,000. Landscape Capital Management L.L.C. purchased a new position in shares of Dyadic International in the third quarter worth $190,000. Finally, Truist Financial Corp grew its position in Dyadic International by 30.5% during the third quarter. Truist Financial Corp now owns 326,200 shares of the biotechnology company’s stock valued at $385,000 after buying an additional 76,200 shares during the period. Hedge funds and other institutional investors own 27.95% of the company’s stock.

Dyadic International Stock Down 7.2%

NASDAQ:DYAI traded down $0.05 during midday trading on Thursday, reaching $0.68. 224,072 shares of the stock traded hands, compared to its average volume of 161,340. Dyadic International has a 12-month low of $0.65 and a 12-month high of $1.35. The business has a 50-day moving average of $0.79 and a two-hundred day moving average of $0.84. The company has a debt-to-equity ratio of 4.08, a quick ratio of 2.42 and a current ratio of 2.42. The stock has a market capitalization of $24.67 million, a PE ratio of -2.96 and a beta of 1.17.

Dyadic International (NASDAQ:DYAI – Get Free Report) last posted its earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). Dyadic International had a negative net margin of 192.40% and a negative return on equity of 1,005.45%. The firm had revenue of $1.11 million for the quarter, compared to analysts’ expectations of $0.90 million. On average, equities analysts forecast that Dyadic International will post 0.13 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Dyadic International in a report on Friday, March 27th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $3.00.

View Our Latest Research Report on Dyadic International

Dyadic International Company Profile

(Get Free Report)

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.